<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Quotient Limited

    Quotient Limited

    We are an established, commercial-stage diagnostics company committed to reducing ...

    We are an established, commercial-stage diagnos...

    Filing Type:    PU
    ProQR Therapeutics N.V.

    ProQR Therapeutics N.V.

    We are ProQR, a company on a mission to create new medicines for patients in need....

    We are ProQR, a company on a mission to create ...

    Filing Type:    PU
    Protagonist Therapeutics, Inc.

    Protagonist Therapeutics, Inc.

    Protagonist Therapeutics is a clinical stage biopharmaceutical company that utiliz...

    Protagonist Therapeutics is a clinical stage bi...

    Filing Type:    PU
    Life Imaging Fla, Inc.

    Life Imaging Fla, Inc.

    Our mission is to educate and provide an affordable early detection system for the...

    Our mission is to educate and provide an afford...

    Amount Raised:    $32,726.00
    Fundraising Status:    EC
    Filing Type:    CF
    Inogen, Inc

    Inogen, Inc

    Inogen’s mission to improve the quality of life of supplemental oxygen users beg...

    Inogen’s mission to improve the quality of li...

    Filing Type:    PU
    Surmodics, Inc.

    Surmodics, Inc.

    Following two acquisitions of Creagh Medical and NorMedix – recognized innovator...

    Following two acquisitions of Creagh Medical an...

    Filing Type:    PU
    PDS Biotechnology Corporation

    PDS Biotechnology Corporation

    PDS Biotechnology has a growing pipeline of clinical-stage immunotherapies to trea...

    PDS Biotechnology has a growing pipeline of cli...

    Filing Type:    PU
    Celsion Corporation

    Celsion Corporation

    Celsion Corporation is a fully integrated biopharmaceutical company focused on dev...

    Celsion Corporation is a fully integrated bioph...

    Filing Type:    PU
    Checkpoint Therapeutics, Inc.

    Checkpoint Therapeutics, Inc.

    Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage, immuno-oncol...

    Checkpoint Therapeutics, Inc. (“Checkpoint”...

    Filing Type:    PU
    ASLAN Pharmaceuticals Limited

    ASLAN Pharmaceuticals Limited

    ASLAN Pharmaceuticals is a clinical-stage oncology-focused biotechnology company d...

    ASLAN Pharmaceuticals is a clinical-stage oncol...

    Filing Type:    PU
    Biocept, Inc.

    Biocept, Inc.

    Biocept, Inc. is a molecular diagnostics company with commercialized assays for lu...

    Biocept, Inc. is a molecular diagnostics compan...

    Filing Type:    PU
    ArQule, Inc.

    ArQule, Inc.

    ArQule is a biopharmaceutical company engaged in the research and development of t...

    ArQule is a biopharmaceutical company engaged i...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.